152 related articles for article (PubMed ID: 35400665)
1. Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen.
Yu H; Mi L; Qi F; Wang X; Ye Y; Li M; Wang D; Ding N; Wang X; Song Y; Zhu J; Xie Y
Aging (Albany NY); 2022 Apr; 14(7):3203-3215. PubMed ID: 35400665
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of dose-adjusted Berlin-Frankfurt-Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma.
Xie Y; Zhang Y; Zheng W; Wang X; Lin N; Tu M; Ping L; Ying Z; Zhang C; Liu W; Deng L; Song Y; Zhu J
Med Oncol; 2015 Apr; 32(4):110. PubMed ID: 25752875
[TBL] [Abstract][Full Text] [Related]
3. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma.
Feng X; Li L; Wu J; Zhang L; Sun Z; Li X; Wang X; Yu H; Chang Y; Wu X; Zhou Z; Wang G; Li W; Li Z; Zhang X; Zhang M
Oncologist; 2019 Nov; 24(11):e1123-e1131. PubMed ID: 30952822
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Münster Chemotherapy in Adult Acute Lymphoblastic Leukemia.
Aladag E; Aktimur SH; Aydın Ö; Demiroglu H; Buyukasik Y; Aksu S; Ozcebe OI; Haznedaroglu IC; Sayinalp N; Turgut M; Goker H
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):147-153. PubMed ID: 33451957
[TBL] [Abstract][Full Text] [Related]
5. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and prognostic factors in children with B-cell lymphoblastic lymphoma (LBL) treated according to on modified BFM-90 protocol: Experience from a Tertiary cancer care center in India.
Vijayasekharan K; Kc A; Prasad M; Dhamne C; Roy Moulik N; Shet T; Sridhar E; Laskar S; Kembhavi S; Shah S; Gujral S; Narula G; Banavali SD
Pediatr Hematol Oncol; 2022 Aug; 39(5):427-440. PubMed ID: 35179438
[TBL] [Abstract][Full Text] [Related]
7. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
Sun XF; Jiang WQ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Li YH; Zhou ZM; Zhen ZJ; Xia Y; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1687-91. PubMed ID: 15601561
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
10. A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience.
Li C; Wuxiao ZJ; Chen X; Chen G; Lu Y; Xia Z; Liang Y; Wang H
Cancer Res Treat; 2020 Apr; 52(2):573-585. PubMed ID: 32019289
[TBL] [Abstract][Full Text] [Related]
11. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of treatment response and prognostic factors of T-LBL patients treated with pediatric-like ALL therapy following HSCT].
Wang HT; Dong Y; Gao XT; Wan Z; Zhao YX; Liu YM; Liu L
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):387-393. PubMed ID: 32536135
[No Abstract] [Full Text] [Related]
13. A childhood chemotherapy protocol improves overall survival among adults with T-lymphoblastic lymphoma.
Zhu MY; Wang H; Huang CY; Xia ZJ; Chen XQ; Geng QR; Wang WD; Wang L; Lu Y
Oncotarget; 2016 Jun; 7(25):38884-38891. PubMed ID: 27150061
[TBL] [Abstract][Full Text] [Related]
14. Initial Experiences in Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Treated with the Modified BFM 2002 Protocol in a Resource-Constrained Setting.
Jinwala P; Patidar R; Bansal S; Asati V; Shrivastava SP; Elhence A; Patel S; Chitalkar PG
South Asian J Cancer; 2023 Oct; 12(4):378-383. PubMed ID: 38130284
[TBL] [Abstract][Full Text] [Related]
15. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
16. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.
Reiter A; Schrappe M; Ludwig WD; Tiemann M; Parwaresch R; Zimmermann M; Schirg E; Henze G; Schellong G; Gadner H; Riehm H
Blood; 2000 Jan; 95(2):416-21. PubMed ID: 10627444
[TBL] [Abstract][Full Text] [Related]
17. Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantation.
Hu M; Wang H; Wang L; Yang M; Lou Y; Jin J
Medicine (Baltimore); 2018 Jul; 97(28):e11374. PubMed ID: 29995776
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
Möricke A; Zimmermann M; Reiter A; Henze G; Schrauder A; Gadner H; Ludwig WD; Ritter J; Harbott J; Mann G; Klingebiel T; Zintl F; Niemeyer C; Kremens B; Niggli F; Niethammer D; Welte K; Stanulla M; Odenwald E; Riehm H; Schrappe M
Leukemia; 2010 Feb; 24(2):265-84. PubMed ID: 20010625
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of modified Berlin-Frankfurt-Münster-90 regimen in adults with T-lymphoblastic lymphoma: a single-center experience.
Wang K; Chen X; Wuxiao Z; Wang Z; Sun X; Zeng Z; Li S; Xia ZJ
Leuk Lymphoma; 2014 Aug; 55(8):1800-5. PubMed ID: 24475787
[TBL] [Abstract][Full Text] [Related]
20. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
